Europe PMC

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Patient-Reported Outcomes During and After Hepatitis C Virus Direct-Acting Antiviral Treatment Among People Who Inject Drugs.

Show less

Collaborators (95)

Author information

Affiliations

  • 1. The Kirby Institute, University of New South Wales (UNSW) Sydney, Sydney, NSW, Australia.
      Authors
    • Cheng Q 1
    • Cunningham EB 1
    • Shih S 1
    • Marks P 1
    • Hajarizadeh B 1
    • Grebely J 1
    (6 authors)
  • 2. The Kirby Institute, University of New South Wales (UNSW) Sydney, Sydney, NSW, Australia; Department of Health Sciences, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW, Australia.
      Authors
    • Amin J 2
    (1 author)
  • 3. Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada; Département de médecine, Université de Montréal, Montréal, QC, Canada.
      Authors
    • Bruneau J 3
    (1 author)
  • 4. Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, England, UK.
      Authors
    • Artenie AA 4
    (1 author)
  • 5. Infection Prevention and Control, Michael Garron Hospital, Toronto, ON, Canada.
      Authors
    • Powis J 5
    (1 author)
    • Show all (17)

ORCIDs linked to this article

Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research, 13 Jan 2023, 26(6):883-892
https://doi.org/10.1016/j.jval.2022.12.016 PMID: 36646278 

Abstract 

Objectives

People who inject drugs (PWID) are at a high risk of hepatitis C virus (HCV) infection. HCV cure is associated with improved patient-reported outcomes (PROs), but there are little data among PWID. This study aimed to assess the change in PROs during and after HCV direct-acting antiviral (DAA) treatment.

Methods

This analysis used data from 2 clinical trials of DAA treatment in PWID. PROs assessed included health-related quality of life, social functioning, psychological distress, housing, and employment. Generalized estimating equations and group-based trajectory modeling were used to assess changes in PROs over time.

Results

No significant changes in the 3-level version of EQ-5D scores, EQ visual analogue scale scores, social functioning, psychological distress, and housing were observed over the 108-week study period. There was a significant increase in the proportion of participants employed (18% [95% confidence interval (CI) 12%-23%] at baseline to 28% [95% CI 19%-36%] at the end of the study). Participants were more likely to be employed at 24 weeks and 108 weeks after commencing treatment. Having stable housing increased the odds of being employed (odds ratio 1.70; 95% CI 1.00-2.90). The group-based trajectory modeling demonstrated that most outcomes remained stable during and after DAA treatment.

Conclusions

Although no significant improvement was identified in health-related quality of life after HCV DAA treatment, there was a modest but significant increase in employment during study follow-up. The study findings support the need for multifaceted models of HCV care for PWID addressing a range of issues beyond HCV treatment to improve quality of life.

Full text links 

Read article at publisher's site: https://doi.org/10.1016/j.jval.2022.12.016

Citations & impact 

Impact metrics

3
Citations
Jump to Citations

Citations of article over time

Alternative metrics

Altmetric item for https://www.altmetric.com/details/141410660
Altmetric
Discover the attention surrounding your research
https://www.altmetric.com/details/141410660

Smart citations by scite.ai
Smart citations by scite.ai include citation statements extracted from the full text of the citing article. The number of the statements may be higher than the number of citations provided by EuropePMC if one paper cites another multiple times or lower if scite has not yet processed some of the citing articles.
Explore citation contexts and check if this article has been supported or disputed.
https://scite.ai/reports/10.1016/j.jval.2022.12.016

Supporting
Mentioning
Contrasting
1
0
0

Article citations

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.

Funding 

Funders who supported this work.

AbbVie

    Department of Health and Ageing, Australian Government

      Gilead Sciences